NICE opens consultation on Janssen's Stelara after issuing no in draft guidance
This article was originally published in Scrip
Executive Summary
Janssen (Johnson & Johnson) and other stakeholders now have until 17 January 2014 to submit comments on NICE’s draft guidance rejecting Stelara (ustekinumab) for use on the NHS to treat psoriatic arthritis.